EDAP May 2023 5.000 call
| Previous Close | 6.50 |
| Open | 6.50 |
| Bid | 5.50 |
| Ask | 6.10 |
| Strike | 5.00 |
| Expire Date | 2023-05-19 |
| Day's Range | 6.50 - 6.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
- GlobeNewswire
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy
Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as compared to EUR 9.9 million (USD 11.7 million) for the full-year 2021Record Q4 2022 total revenue of EUR 15.7 million ($16.2 million) versus EUR 14.0 million ($15.9 million) for Q4 2021Ended the year with a strong cash position of EUR 63.1 million ($67.5 million) as of December 31, 2022Ryan Rhodes to suc
- InvestorPlace
7 Biotech Stocks Sitting in the Sweet Spot
Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotech companies can pour millions into research and development and have nothing to show with it. Biotech companies are on the leading edge of scientific innovation, and they bring in massive profits if they develop a drug that’s deemed to be safe and marketable. Small biotech companies that have potentially attractive d
- GlobeNewswire
EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23
Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP) The HIFU treated arm showed significant benefits across multiple side effect and quality-of-life measures LYON, France, March 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a recent presentation of positive results from a large, multicenter, non-in
